89 reports

The high prevalence of autoimmune diseases is one of the major drivers in the market.

  • Chronic Pain
  • United States
  • AbbVie Inc.
  • Amgen Inc.
  • Biogen Idec Inc.
  • Canada Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • India Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022

MediPoint: Rheumatoid Arthritis Testing - Global Analysis and Market Forecasts Summary Rheumatoid Arthritis (RA) is the commonest autoimmune disease in humans. The disease is prevalent in all ethnic groups, affecting approximately 1.0% of the world population. Presently there is a huge presence of unmet patient needs for...

  • Chronic Pain
  • Market Size
  • Beckman Coulter, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlobalData's company
  • RHEUMATOID ARTHRITIS TO DOMINATE THE ASIAN AUTOIMMUNE DISEASE
  • AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2015-2022 (USD MILLION)

The autoimmune disease diagnosis market projected to grow at a CAGR of 8.9% during the forecast period. The global autoimmune disease diagnosis market is expected to reach USD 4.73 billion by 2022 from USD 3.09 billion in 2017, at a CAGR of 8.9%. Factors driving the growth of this market include the rising incidence of...

  • Chronic Pain
  • North America
  • United States
  • Forecast
  • Thermo Fisher Scientific, Inc.
  • Autoimmune and inflammatory diseases
  • RHEUMATOID ARTHRITIS

About Autoimmune and Inflammatory Immunomodulators Immunomodulators are the drugs that help to regulate the immune system. These drugs either stimulate the weak immune systems or moderate the overactive immune systems. Though many drugs are available in the market, there still exists a huge unmet need in the autoimmune and inflammatory...

  • Chronic Pain
  • Forecast
  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.

Rheumatoid arthritis (RA) is an autoimmune disease where antibodies act against the body' s own cells and tissues, primarily the joints.

  • Chronic Pain
  • World
  • Market Segment
  • Smith & Nephew Plc
  • Stryker Corporation

Patients in more severe stages of the disease may need biologic response modifiers.

  • Anti Rheumatic
  • Chronic Pain
  • Monoclonal Antibody
  • Therapy
  • United States

IN ADDITION, IT IS BEING INVESTIGATED AS A POSSIBLE TREATMENT FOR OTHER AUTOIMMUNE DISEASES AS WELL.

  • Chronic Pain
  • Neurological Disorder
  • World
  • Forecast
  • Antares Pharma, Inc.

COMPANY OVERVIEW Setpoint Medical is a biomedical technology company that develops bioelectronic therapies for the treatment of patients suffering from inflammatory autoimmune diseases, such as rheumatoid arthritis and Crohn' s disease.

  • Chronic Pain
  • East Asia
  • North America
  • United States
  • Forecast
  • INTRODUCTION

The basic difference between rheumatoid arthritis and osteoarthritis is that the rheumatoid arthritis is an autoimmune disease characterized by an overactive, misdirected immune system while osteoarthritis is a disease of the cartilage of joints, and it is not a systemic

  • Chronic Pain
  • United States
  • Asterias Biotherapeutics, Inc.
  • BioTime, Inc.
  • OrthoCyte Corporation

This is mainly due to increase prevalence of autoimmune diseases and higher adoption of novel RA diagnostic kits.

  • Arthritis
  • Chronic Pain
  • World
  • Forecast
  • Market Shares

Annals of the Rheumatic Diseases; ##(##): ##-##.

  • Chronic Pain
  • Japan
  • Spain
  • United States
  • Forecast
  • Introduction
  • Vendor landscape

DEVELOPS DRUGS FOR INFLAMMATORY DISEASES, CARDIOVASCULAR DISEASES, AUTOIMMUNE DISEASES, METABOLIC DISEASES, DEPRESSION, AND AGE-RELATED DISEASES.

  • Chronic Pain
  • World
  • Ampio Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.

Its R& D is focused on the following six therapeutic areas: endocrine diseases, cancer, autoimmune diseases, neurological disorders, musculoskeletal disorders, and cardiovascular diseases.

  • Chronic Pain
  • World
  • Actavis plc
  • Eli Lilly & Co.
  • Pfizer Inc.

Pfizer obtained worldwide exclusive rights to Dekavil for autoimmune diseases.

  • Chronic Pain
  • North America
  • United States
  • AbbVie Inc.
  • Astellas Pharma Inc.

While RA testing is one of the most lucrative segments within autoimmune testing, the market growth of RA testing will be hampered by the high rate of false positive results and the pressure for healthcare providers to control cost.

  • Arthritis
  • Chronic Pain
  • Europe
  • Demand
  • Market Shares

While RA testing is one of the most lucrative segments within autoimmune testing, the market growth of RA testing will be hampered by the high rate of false positive results and the pressure for healthcare providers to control cost.

  • Arthritis
  • Chronic Pain
  • North America
  • Demand

While RA testing is one of the most lucrative segments within autoimmune testing, the market growth of RA testing will be hampered by the high rate of false positive results and the pressure for healthcare providers to control cost.

  • Chronic Pain
  • APAC
  • Demand
  • Forecast
  • Market Shares
  • REFERENCES

Prevalence of serological markers for celiac disease in patients with autoimmune rheumatologic diseases in Belo Horizonte, MG, Brazil.

  • Arthritis
  • Chronic Disease
  • Chronic Pain
  • Pathology
  • Untitled
  • Rheumatoid Arthritis

About Hip Implant Hip replacement is an orthopedic surgical procedure in which the damaged hip joint is replaced with an artificial joint. An artificial joint usually made from metal, ceramic, or polymeric components. The surgery is performed either by traditional technique or by minimally invasive technique. The hip replacement surgery...

  • Chronic Pain
  • Biomet, Inc.
  • DePuy Synthes, Inc.
  • Smith & Nephew Plc
  • Stryker Corporation

Rheumatoid arthritis

4385 5000 3900
  • SOURCES
  • Strengths and Limitations

Tobón GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis.

  • Chronic Pain
  • Japan
  • United States
  • Pfizer Inc.
  • Roche Group
  • Rheumatoid Arthritis
  • Risk Factors Associated with Rheumatoid Arthritis

About Joint Reconstruction Joint reconstruction is a procedure in which a damaged or dysfunctional joint or tissue is replaced by an artificial prosthesis. Artificial prostheses are made up of different types of materials, including metals, plastics, and ceramics. The common types of joint replacement procedures include hip and knee replacement...

  • Chronic Pain
  • Biomet, Inc.
  • DePuy Synthes, Inc.
  • Smith & Nephew Plc
  • Stryker Corporation
  • PIPELINE BY CHEMOCENTRYX INC, H2 2017
  • DEC 16, 2009: CHEMOCENTRYX INITIATES PHASE 2 CLINICAL TRIAL OF CCX354 FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Pipeline Review, H2 2017 Summary C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) pipeline Target...

  • Chronic Pain
  • Therapy
  • United States
  • World
  • ChemoCentryx, Inc.
  • GLAXOSMITHKLINE PLC

Myasthenia Gravis - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H2 2018, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape. Myasthenia gravis is autoimmune...

  • Chronic Pain
  • Mental Health
  • United States
  • Product Initiative
  • Protalex, Inc.
  • NORTH AMERICA TO COMMAND THE LARGEST MARKET SHARE IN 2018
  • UK: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)

The autoinjectors market is projected to grow at a CAGR of 24.2% during the forecast period. The global autoinjectors market is expected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period. Growing prevalence of targeted therapies, rising incidence...

  • Chronic Pain
  • Drug Delivery
  • Injectable Delivery
  • Therapy
  • Amgen Inc.
  • JUN 28, 2016: NEUROMAX ANNOUNCES START PHASE 1 CLINICAL TRIAL OF AQU-005 FOR THE TREATMENT OF NEUROPATHIC PAIN

A team of Weizmann Institute scientists has turned the tables on an autoimmune disease.

  • Chronic Pain
  • Hospital
  • Therapy
  • World
  • Product Initiative
  • PIPELINE BY CHEMOCENTRYX, INC., H1 2016
  • NOV 09, 2010: CHEMOCENTRYX REPORTS FAVORABLE PHASE I RESULTS FOR CCX354 IN RHEUMATOID ARTHRITIS AT ANNUAL AMERICAN COLLEGE OF RHEUMATOLOGY MEETING

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Pipeline...

  • Chemokine
  • Chronic Pain
  • Hospital
  • Therapy
  • ChemoCentryx, Inc.
  • VBY-285 - DRUG PROFILE
  • Pipeline by Sanofi, H2 2017

Its multiple candidates serve therapeutic areas such as neuroapathic pain, autoimmune diseases, liver fibrosis, and cancer.

  • Chronic Pain
  • United States
  • World
  • Product Initiative
  • Medivir UK Ltd.
  • FILGOTINIB - DRUG PROFILE
  • FILGOTINIB - DRUG PROFILE

LTD IS DEVELOPING JTE-## FOR THE TREATMENT OF AUTOIMMUNE/ ALLERGIC DISEASES LIKE ATOPIC DERMATITIS.

  • Chronic Pain
  • Hospital
  • United States
  • Product Initiative
  • Incyte Corporation
  • Chronic Pain

Poor circulation is usually caused by tobacco use, diabetes or various autoimmune diseases (diseases where the body makes antibodies that fight against itself) such as lupus or rheumatoid arthritis.

  • Chronic Pain
  • United States
  • Egalet Corporation
  • Pfizer Inc.
  • Zogenix, Inc.
  • Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile

The molecules developed by companies in Phase II, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Chronic Pain
  • Therapy
  • Australia
  • World
  • Product Initiative